

# **GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION**

JULY 2018



**GUIDELINES**



# **GUIDELINES FOR THE CARE AND TREATMENT OF PERSONS DIAGNOSED WITH CHRONIC HEPATITIS C VIRUS INFECTION**

JULY 2018

Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection

**ISBN 978-92-4-155034-5**

**© World Health Organization 2018**

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions expected, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Layout: 400.co.uk

Printed in France

# CONTENTS

<b>ACKNOWLEDGEMENTS</b>	<b>vi</b>
<b>ABBREVIATIONS AND ACRONYMS</b>	<b>ix</b>
<b>GLOSSARY OF TERMS</b>	<b>xi</b>
<b>EXECUTIVE SUMMARY</b>	<b>xii</b>
<b>CHAPTER 1. SCOPE AND OBJECTIVES</b>	<b>1</b>
1.1 Objectives	1
1.2 New developments and rationale for an update of the guidelines	1
1.3 Target audience	2
1.4 Scope of the guidelines	2
1.5 Related guidelines	3
1.6 Guiding principles	3
<b>CHAPTER 2. BACKGROUND</b>	<b>4</b>
2.1 The challenge of HCV elimination	4
2.1.1 Natural history of HCV infection	5
2.1.2 Natural history of HIV/HCV coinfection	6
2.1.3 Routes of transmission	7
2.2 Direct-acting antivirals	8
2.2.1 Summary of the currently available pangenotypic DAA combinations	8
2.3 Access to direct-acting antivirals	9
<b>CHAPTER 3. METHODS</b>	<b>10</b>
3.1 WHO guidelines development process	10
3.2 Formulation of recommendations	10
3.3 Roles	11
3.4 Declarations of interest and management of conflicts of interest	11
3.5 Dissemination and updating of the guidelines	12
3.6 Evidence that informed the recommendations	13
3.6.1 Systematic reviews and meta-analyses	13
3.6.2 Modelling	13
3.6.3 Feasibility survey	14
3.6.4 Cost-effectiveness analyses	14
3.6.5 Values and preferences	14

<b>CHAPTER 4. RECOMMENDATIONS</b>	<b>15</b>
4.1 Treatment with direct-acting antiviral agents: when to start treatment	15
4.1.1 Summary of the evidence	15
4.1.2 Rationale for the recommendation	17
4.1.3 Implementation considerations	21
4.1.4 Research gaps	21
4.2 Treatment of adults with direct-acting antiviral agents: what treatment to use	22
4.2.1 Summary of the evidence	22
4.2.2 Rationale for the recommendation	24
4.2.3 Implementation considerations	26
4.2.4 Research gaps	26
4.3 Treatment of adolescents (12–17 years) and deferral of treatment in children (<12 years of age)	26
4.3.1 Background	27
4.3.2 Summary of the evidence	28
4.3.3 Rationale for the recommendations	29
4.3.4 Implementation considerations	31
4.3.5 Research gaps	32
<b>CHAPTER 5. CLINICAL CONSIDERATIONS</b>	<b>33</b>
5.1 Clinical assessment of persons with HCV infection prior to treatment	34
5.1.1 Drug–drug interactions	35
5.1.2 Monitoring for treatment toxicity	36
5.1.3 Monitoring for treatment response	37
5.2 Clinical considerations for specific populations	37
5.2.1 Persons with HIV/HCV coinfection	37
5.2.2 Persons with HBV/HCV coinfection	38
5.2.3 Persons with cirrhosis	38
5.2.4 Persons with chronic kidney disease	39
5.2.5 Persons with TB/HCV coinfection	39
5.2.6 Retreatment of persons with failure of DAA therapy	40
<b>CHAPTER 6. SIMPLIFIED SERVICE DELIVERY FOR A PUBLIC HEALTH APPROACH TO TESTING, CARE AND TREATMENT FOR HCV INFECTION</b>	<b>41</b>
6.1 National planning for HCV elimination	42
6.2 Simple standardized algorithms	42
6.3 Strategies to strengthen linkage from testing to care	42
6.4 Integrated testing, care and treatment	43
6.4.1 Providing testing for HCV infection in different settings	43
6.4.2 Integrating the diagnosis of hepatitis with diagnostic platforms and laboratory services used for other infections	44
6.4.3 Integrated service delivery of care, prevention and treatment	44

6.5 Decentralized services	45
6.5.1 Task-sharing	45
6.5.2 Differentiated HCV care and treatment	45
6.6 Community engagement and peer support, including addressing stigma and discrimination in the general population	47
6.7 Strategies for more efficient procurement and supply management of medicines and diagnostics	48
6.8 Data systems for monitoring the quality and cascade of care	50

## **CHAPTER 7. PUBLIC HEALTH CONSIDERATIONS FOR SPECIFIC POPULATIONS**

7.1 People who inject drugs	52
7.1.1 Background	52
7.1.2 Service delivery considerations	52
7.2 People in prisons and other closed settings	53
7.2.1 Background	53
7.2.2 Service delivery considerations	53
7.3 Indigenous Peoples	54
7.3.1 Background	54
7.3.2 Service delivery considerations	54
7.4 Men who have sex with men	55
7.4.1 Background	55
7.4.2 Service delivery considerations	55
7.5 Sex workers	56
7.5.1 Background	56
7.5.2 Service delivery considerations	56

## **REFERENCES**

## **ANNEXES**

Annex 1: Declarations of interest, Guidelines Development Group	80
Annex 2: Declarations of interest, External Review Group	83

### **Web annexes**

Annex 1: Decision-making table, PICO question on when to treat
Annex 2: Decision-making table, PICO question on how to treat
Annex 3.1: Adult HCV treatment systematic review
Annex 3.2: Adult HCV treatment systematic review; supporting evidence
Annex 4: Modelling analyses
Annex 5: Summary of available non-pangenotypic regimens
Annex 6: Decision-making table, PICO question on children and adolescents
Annex 7: Values and preferences surveys
Annex 8: Summary of findings tables

# ACKNOWLEDGEMENTS

Many individuals from a range of backgrounds and specialties have contributed to the development of this guidance. WHO is sincerely grateful for their time and support.

## Guidelines Development Group

The chairs of the Guidelines Development Group were Saeed Sadiq Hamid (The Aga Khan University & Hospital, Pakistan) and Karla Thornton (University of New Mexico, USA). Roger Chou (Oregon Health & Science University, USA) was the guidelines methodologist.

The following experts served on the Guidelines Development Group: Evaldo Stanislau Affonso Araújo (University of São Paulo Hospital das Clínicas Infectious Diseases, Brazil); Rakesh Aggarwal (Sanjay Gandhi Postgraduate Institute of Medical Sciences, India); Anton Basenko (International Network of People who Use Drugs (INPUD), Ukraine); Davaadorj Duger (National University of Medical Sciences, Mongolia); Manal Hamdy El-Sayed (Ain Shams University, Egypt); Charles Gore (World Hepatitis Alliance, UK; presently with Medicines Patent Pool, Switzerland); Azumi Ishizaki (Kanazawa University, Japan and Hanoi, Viet Nam); Giten Khwairakpam (TREAT Asia/AmFAR, Thailand); Olufunmilayo Lesi (University of Lagos, Nigeria); Niklas Luhmann (Médecins du Monde, France); Constance Mukabatsinda (Kigali University Teaching Hospital, Rwanda); Francesco Negro (Geneva University Hospitals, Switzerland); David R. Nelson (University of Florida, USA); Ponsiano Ocam (Makerere University, Uganda); Jürgen Rockstroh (University of Bonn, Germany); Regina

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_25716](https://www.yunbaogao.cn/report/index/report?reportId=5_25716)

